Viking Therapeutics, Inc. Q2 2026 Earnings Recap

Shares declined 2.2% following Viking Therapeutics’ Q2 report as investors digested widening net losses driven by sharply higher R&D and G&A expenses without material clinical milestones or revenue to offset the increased spend.

Key Takeaways

• Net loss widened to $128.1 million ($1.10 per share) in Q2 2026, nearly doubling from $65.6 million in Q2 2025.
• R&D expenses surged 92% year-over-year to $115.8 million, reflecting ramped clinical studies, personnel costs, and consulting fees.
• General and administrative costs increased modestly to $16.9 million, driven by higher legal, patent, and consulting expenses.
• Cash and equivalents declined to $502 million from $706 million at the end of 2025, indicating significant cash burn.
• Pipeline activity continued on plan with Phase III VANQUISH trials fully enrolled and a Phase I study initiated, but no data or commercial inflection points reported this quarter.